Most Popular

1
Industry experts predicts tough choices as NewJeans' ultimatum nears
2
Opposition chief acquitted of instigating perjury
3
Seoul city opens emergency care centers
4
Jung's paternity reveal exposes where Korea stands on extramarital babies
5
[Exclusive] Hyundai Mobis eyes closer ties with BYD

6
[Herald Review] 'Gangnam B-Side' combines social realism with masterful suspense, performance
7
Why S. Korean refiners are reluctant to import US oil despite Trump’s energy push
8
Agency says Jung Woo-sung unsure on awards attendance after lovechild revelations
9
Prosecutors seek 5-year prison term for Samsung chief in merger retrial
10
UN talks on plastic pollution treaty begin with grim outlook

NewsletterSubscribe

Start your day with a roundup of key stories from The Korea Herald with news and comment on all that’s happening in Korea.

Genexine’s COVID-19 drug to begin phase 1 trial in Korea

By Lim Jeong-yeo

Published : Aug. 7, 2020 - 18:09

- Link copied

Genexine‘s COVID-19 treatment candidate GX-17 was given the Korean drug authority’s grant to proceed to phase 1 human trials, Friday.

GX-17 is a protein drug recombining human IL-7 and hybrid Fc (hyFc) that the company had been developing as an anti-cancer treatment. It is a T-Cell growth factor that proliferates a patient‘s immune cells, by which it slows the progression of an illness and hastens recovery.

With the addition of GX-17, South Korea now has 13 treatment researches and two vaccine researches ongoing to tackle COVID-19.

By Lim Jeong-yeo (kaylalim@heraldcorp.com)

Genexine’s COVID-19 drug to begin phase 1 trial in Korea

More from Headlines